全文获取类型
收费全文 | 4510篇 |
免费 | 337篇 |
国内免费 | 115篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 160篇 |
妇产科学 | 32篇 |
基础医学 | 1489篇 |
口腔科学 | 86篇 |
临床医学 | 374篇 |
内科学 | 921篇 |
皮肤病学 | 82篇 |
神经病学 | 265篇 |
特种医学 | 51篇 |
外国民族医学 | 1篇 |
外科学 | 166篇 |
综合类 | 506篇 |
预防医学 | 380篇 |
眼科学 | 63篇 |
药学 | 237篇 |
2篇 | |
中国医学 | 55篇 |
肿瘤学 | 64篇 |
出版年
2023年 | 62篇 |
2022年 | 77篇 |
2021年 | 163篇 |
2020年 | 121篇 |
2019年 | 155篇 |
2018年 | 132篇 |
2017年 | 124篇 |
2016年 | 147篇 |
2015年 | 146篇 |
2014年 | 249篇 |
2013年 | 291篇 |
2012年 | 200篇 |
2011年 | 199篇 |
2010年 | 187篇 |
2009年 | 173篇 |
2008年 | 155篇 |
2007年 | 138篇 |
2006年 | 163篇 |
2005年 | 152篇 |
2004年 | 137篇 |
2003年 | 124篇 |
2002年 | 122篇 |
2001年 | 88篇 |
2000年 | 89篇 |
1999年 | 100篇 |
1998年 | 80篇 |
1997年 | 73篇 |
1996年 | 83篇 |
1995年 | 86篇 |
1994年 | 95篇 |
1993年 | 71篇 |
1992年 | 66篇 |
1991年 | 62篇 |
1990年 | 67篇 |
1989年 | 49篇 |
1988年 | 54篇 |
1987年 | 41篇 |
1986年 | 48篇 |
1985年 | 72篇 |
1984年 | 77篇 |
1983年 | 67篇 |
1982年 | 55篇 |
1981年 | 39篇 |
1980年 | 38篇 |
1979年 | 24篇 |
1978年 | 2篇 |
1977年 | 6篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1973年 | 2篇 |
排序方式: 共有4962条查询结果,搜索用时 187 毫秒
1.
《Vaccine》2022,40(13):1924-1927
High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers. 相似文献
2.
目的探讨ω-3多不饱和脂肪酸(ω-3 poly unsaturated fatty acids,ω-3 PUFAs)对慢性移植物抗宿主病(chronic graft versus host disease,cGVH)狼疮模型小鼠的免疫调节功能影响。方法单次腹腔注射bm12小鼠淋巴细胞建立cGVH小鼠模型,造模当天分别给予90%ω-3 PUFAs和97%EPA灌胃治疗,持续14 d。通过流式细胞术检测小鼠脾脏淋巴细胞中各免疫指标,ELISA检测小鼠血清中总IgG水平。结果与正常对照组相比,cGVH组明显下调Treg亚群,明显上调TFH细胞、生发中心B细胞和浆细胞亚群;与模型对照组相比,90%ω-3和97%EPA均明显上调Treg亚群,并明显下调TFH细胞、生发中心B细胞和浆细胞亚群;且97%EPA组小鼠血清中总IgG水平明显下降。结论在cGVH狼疮小鼠模型中,ω-3 PUFAs通过增加Treg细胞,减少TFH细胞、生发中心B细胞和浆细胞,抑制IgG的分泌,从而发挥免疫抑制作用,且其免疫抑制作用可能与ω-3 PUFAs含量相关。 相似文献
3.
《Vaccine》2022,40(24):3320-3329
BackgroundCurrently, booster dose is needed after 2 doses of non-live COVID-19 vaccine. With limited resources and shortage of COVID-19 vaccines, intradermal(ID) administration might be a potential dose-sparing strategy.ObjectiveTo determine immunologic response and reactogenicity of ID ChAdOx1 nCoV-19 vaccine (AZD1222,Oxford/AstraZeneca) as a booster dose after completion of 2-dose CoronaVac(SV) in healthy adult.MethodsThis is a prospective cohort study of adult aged 18–59 years who received 2-dose SV at 14–35 days apart for more than 2 months. Participants received ID AZD1222 at fractional low dose(1×1010 viral particles,0.1 ml). Antibody responses were evaluated by surrogate virus neutralization test(sVNT) against delta variant and wild type, and anti-spike-receptor-binding-domain immunoglobulin G(anti-S-RBD IgG) at prior, day14, 28, 90, and 180 post booster. Solicited reactogenicity was collected for 7 days post-booster. Primary endpoint was the differences of sVNT against delta strain ≥ 80% inhibition at day14 and 90 compared with the parallel cohort study of 0.5-ml intramuscular(IM) route.ResultsFrom August2021, 100 adults with median age of 46 years(IQR 41–52) participated. Prior to booster, geometric mean(GM) of sVNT against delta strain was 22.4% inhibition(95 %CI 18.7–26.9) and of anti-S-RBD IgG was 109.3 BAU/ml(95.4–125.1). Post ID booster, GMs of sVNT against delta strain were 95.5% inhibition (95%CI 94.2–96.8) at day14, 73.1% inhibition (66.7–80.2) at day90, and 22.7% inhibition (14.9–34.6) at day180. The differences of proportion of participants achieving sVNT against delta strain ≥ 80% inhibition in ID recipients versus IM were + 4.2% (95 %CI -2.0to10.5) at day14, and ?37.3%(-54.2to-20.3) at day90. Anti-S-RBD IgG GMs were 2037.1 BAU/ml (95%CI 1770.9–2343.2) at day14 and 744.6 BAU/ml(650.1–852.9) at day90, respectively. Geometric mean ratios(GMRs) of anti-S-RBD IgG were 0.99(0.83–1.20) at day14, and 0.82(0.66–1.02) at day90. Only 18% reported feverish, compared with 37% of IM (p = 0.003). Common reactogenicity was erythema at injection site(53%) while 7% reported blister.ConclusionLow-dose ID AZD1222 booster enhanced lower neutralizing antibodies at 3 months compared with IM route. Less systemic reactogenicity occurred, but higher local reactogenicity. 相似文献
4.
5.
6.
7.
8.
Qunchuan Zhuang Aling Shen Liya Liu Meizhu Wu Zhiqing Shen Huixin Liu Ying Cheng Xiaoying Lin Xiangyan Wu Wei Lin Jiapeng Li Yuying Han Xiaoping Chen Qi Chen Jun Peng 《Oncology Letters》2021,22(1)
Valuable diagnostic and prognostic biomarkers are urgently needed for colorectal cancer (CRC), which is one of the leading causes of mortality worldwide. Previous studies have reported altered expression of a mucin-like protein Fc fragment of IgG binding protein (FCGBP) in various types of cancer, but its potential diagnostic, prognostic and immunological roles in CRC remain to be determined. Therefore, the aim of current study was to investigate the potential roles of FCGBP in CRC. The present study investigated FCGBP mutations and changes in its expression levels using a combination of microarray and public dataset analyses, as well as immunohistochemistry. The results demonstrated a 10.5% mutation frequency in the FCGBP coding sequence in CRC tissues, and identified decreased FCGBP mRNA or protein expression levels in colorectal adenoma and CRC (compared with those in normal colorectal tissues from healthy control subjects), including pathologically advanced CRC (stage III+IV vs. I+II). Survival analysis using the GEPIA and Kaplan-Meier Plotter databases revealed that low FCGBP expression levels were associated with short overall, disease-free, relapse-free and event-free survival times in patients with CRC. Notably, analysis using the online Tumor IMmune Estimation Resource database revealed a positive correlation between FCGBP expression levels and the extent of infiltrating immune cells, such as B cells and dendritic cells. Consistently, the expression levels of most markers (51/57) for various types of immune cells were significantly correlated with FCGBP expression levels in CRC tissues. These findings suggested that FCGBP may serve as a diagnostic and prognostic biomarker, and that FCGBP may be associated with immune infiltration in CRC. 相似文献
9.
Marie-Luce Delforge Joëlle Eykmans Deborah Steensels Elena Costa Catherine Donner Isabel Montesinos 《Diagnostic microbiology and infectious disease》2019,93(3):208-212
CMV IgG avidity assays are widely used and can be helpful in pregnant women to date the onset of CMV primary infection; however, these tests are not standardized and sometimes give inconclusive results. We evaluated the performances of Mikrogen recomLine CMV IgG and IgG Avidity compared to the VIDAS CMV IgG Avidity. On a first sample set of 89 sequential sera collected from 40 women with precisely determined onset of CMV primary infection, the combination of Mikrogen recomLine CMV IgG and IgG Avidity showed an accurate interpretation in 83.1% (74/89), an incorrect result in 4.5% (4/89), and an inconclusive result in 12.4% (11/89) and showed a better sensitivity to diagnose infections <14?weeks compared to VIDAS (85.9% vs. 76.9%). On a second sample set of 89 sera with an intermediate VIDAS CMV IgG Avidity, the combination of line immunoassays provided additional information on the time of infection in 79% (70/89) of the samples. This combination of line assays is useful as additional confirmatory testing and can help to date more precisely the onset of CMV primary infection. 相似文献
10.